KAREN HENSON: Open Payments
NPI 1730723933 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,422 in 231 payments from 22 companies in 2025. Trend: 2023 $3,463 · 2024 $4,121 · 2025 $4,422
Food & beverage: $4,422
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $622 |
| Otsuka America Pharmaceutical, Inc. | 23 | $424 |
| Janssen Pharmaceuticals, Inc | 32 | $408 |
| Teva Pharmaceuticals USA, Inc. | 21 | $403 |
| Axsome Therapeutics, Inc. | 13 | $382 |
| Neurocrine BioSciences, Inc. | 18 | $375 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $355 |
| Corium, LLC | 13 | $281 |
| E.R. Squibb & Sons, L.L.C. | 16 | $272 |
| Vanda Pharmaceuticals Inc. | 11 | $162 |
Products named: VRAYLAR, REXULTI, Auvelity, INGREZZA, CAPLYTA, AUSTEDO XR, Azstarys, COBENFY.
Industry payments across TX — which companies pay providers there.
